Companion Animal Pharmaceuticals
Companies developing and commercializing pet medications.
Market snapshot
These figures describe Animal Health Pharmaceuticals (4.11.2), the segment that Companion Animal Pharmaceuticals sits within. They are not figures for Companion Animal Pharmaceuticals on its own.
Within pharmaceutical manufacturing (NAICS 325412/325414); the Census Bureau does not separate animal-health pharmaceuticals, so the segment is not separately sized here.
Business model & economics
Revenue model
Vaccine, parasiticide, and therapeutic product sales
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- High
recurring vaccines, parasiticides, and chronic meds
branded animal-pharma economics
Characteristics
- Companion-animal pharma the growth engine.
- Novel therapies (mAbs, derm, parasiticides) drive growth.
- Production-animal pharma mature and antibiotic-pressured.
Geographic concentration
Animal-health pharmaceutical makers cluster in New Jersey and Massachusetts (human-pharma spillover), with specialized hubs in Utah and Colorado.
U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 325412/325414. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- Animal-health pharma strategics
- Pharma & diversified acquirers
- PE- and VC-backed innovators
What’s driving deals
- Companion-animal novel-therapy innovation.
- Consolidation around global strategics.
- Acquisition of pet-pharma and biologic innovation.
Find Companion Animal Pharmaceuticals acquisition targets
Search Acquisera’s index for companies classified under Companion Animal Pharmaceuticals (4.11.2.2) and build a targeted deal pipeline.
Search companies